Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 11/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | SUCNR1 | Q9BXA5 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428307 | 0.90 | C3AR1 (0.61) | C3AR1NPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL4428359 | 0.90 | C3AR1 (0.51) | C3AR1NPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL4437359 | 0.90 | C3AR1 (0.62) | C3AR1NPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL4431457 | 0.88 | C3AR1 (0.50) | C3AR1NPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL4993959 | 0.87 | C3AR1 (0.70) | C3AR1 | |
| SCHEMBL4431865 | 0.85 | C3AR1 (0.54) | C3AR1NPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL4429631 | 0.84 | C3AR1 (0.47) | C3AR1NPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL4427440 | 0.84 | C3AR1 (0.62) | C3AR1NPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL14090944 | 0.83 | C3AR1 (0.52) | C3AR1NPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL4430935 | 0.83 | C3AR1 (0.77) | C3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125739-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | C3AR1 1/4885NPSR1 474/4885MEN1 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.